Abliva’s Chief Scientific Officer, Eskil Elmér, and the company’s researcher, Imen Chamkha, talk about the discovery of a new therapeutic strategy for mitochondrial disease, how we measure mitochondrial function in the lab, and Abliva’s candidate drug NV354 – a cell-permeable succinate prodrug, in development for the treatment of Leigh syndrome..
source
Abliva – Designing Therapies for Mitochondrial Disease – World Mitochondrial Disease Week 2023
